Clinical Trial Update: Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant [Phase 2]

View source ↗

Summary

Phase 2 study evaluating immunogenicity, reactogenicity, and safety of a herpes simplex glycoprotein D (gD) vaccine with or without adjuvant; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Simplex Infection

Drugs mentioned

• Herpes simplex gD vaccine candidate (gD vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Prophylaxis Herpes Simplex | Phase 2 | Status: COMPLETED